CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate…
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
Albireo Recognizes PFIC Awareness Day 2021
Read the rest here:
Albireo Recognizes PFIC Awareness Day 2021
MYNZ Closes Its First Day of Trading on the Nasdaq Capital Market
Read the original here:
MYNZ Closes Its First Day of Trading on the Nasdaq Capital Market
Jounce Therapeutics to Present at Upcoming Investor Conferences in January
See the rest here:
Jounce Therapeutics to Present at Upcoming Investor Conferences in January
European Medicines Agency Accepts GBT’s Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in…
Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
See the original post:
Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
CEO Dr. Johnson Lau Contracts COVID-19
Read the original:
CEO Dr. Johnson Lau Contracts COVID-19
Tarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of Directors
The rest is here:
Tarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of Directors
Medicenna Establishes At-the-Market Sales Facility
See more here:
Medicenna Establishes At-the-Market Sales Facility
Trevena, Inc. Announces Publication Highlighting GI Tolerability Profile of OLINVYK™ (oliceridine) injection in Pain and Therapy
Matinas BioPharma to Participate in Annual Piper Sandler Healthcare Conference
Immunicum AB and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies
Aquestive Therapeutics Completes FDA Type A Meeting on Libervant
Read the original here:
Aquestive Therapeutics Completes FDA Type A Meeting on Libervant
Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting
EXMceuticals Provides Bi-Weekly Default Status Report
Excerpt from:
EXMceuticals Provides Bi-Weekly Default Status Report